Researchers in the United Kingdom are launching a comprehensive study to evaluate a specialized pain management program designed for patients with endometriosis, a systemic inflammatory condition where cells similar to those lining the uterus develop abnormally in other areas of the body, including the bowel and lungs.
The condition frequently goes undiagnosed for extended periods, and currently has no cure. Patients often experience severe pain that significantly impacts their careers, relationships, education, and mental health. Many continue suffering despite surgical interventions or medication, and diagnostic delays mean individuals may endure years of debilitating symptoms before receiving proper identification of their condition.
The five-year study, funded by the National Institute for Health and Care Research, is being conducted by the University of Aberdeen and NHS Grampian. Researchers will assess whether a personalized 12-week endometriosis-specific pain management program can provide more effective outcomes than standard care alone. The program incorporates cognitive behavioral therapy-informed psychotherapy, specialist physiotherapy, guidance on relationships and communication, and medication optimization to minimize side effects. Eligible pre-menopausal women will be randomly assigned to receive either the new program combined with standard care or standard care exclusively, with outcomes compared between the groups.
Lead researcher Dr. Lucky Saraswat, a consultant gynaecologist at NHS Grampian, emphasized that endometriosis remains one of the most prevalent yet under-researched causes of chronic pain. If proven effective, the program could provide an alternative treatment option for patients who prefer to avoid repeated surgery or hormonal therapies, or who are planning pregnancy. The study will also evaluate the cost-effectiveness of the intervention to determine its viability as a broader clinical option.
Supporting organizations, including Endometriosis UK, have welcomed the research initiative as addressing a critical gap in treatment options for millions of affected individuals worldwide.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI